Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
signs and symptoms pathological conditions | D013568 |
Brand Name | Status | Last Update |
---|---|---|
isoptin sr | 2008-03-11 | |
tarka | New Drug Application | 2012-02-13 |
trandolapril and verapamil hydrochloride | ANDA | 2019-09-30 |
verapamil | ANDA | 2011-08-11 |
verapamil hydrochloride | ANDA | 2014-05-27 |
verapamil hci | New Drug Application | 2024-02-26 |
verapamil hcl | ANDA | 2019-06-03 |
verapamil hydrochloride | NDA authorized generic | 2025-03-25 |
verapamil hydrochloridepm | ANDA | 2010-06-04 |
verelan | New Drug Application | 2023-02-22 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | 2 | 7 | 6 | 17 |
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 1 | 5 | 4 | 5 | 16 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 4 | 1 | 3 | 4 | 12 |
Syndrome | D013577 | — | — | — | 1 | 1 | 3 | 1 | 6 |
Coronary artery disease | D003324 | — | I25.1 | — | 1 | — | 2 | 2 | 5 |
Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | 2 | 1 | 4 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | 1 | 1 | 4 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 1 | 3 | 4 |
Infarction | D007238 | EFO_0009463 | — | — | — | — | 1 | 3 | 4 |
Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | 1 | 1 | — | 2 | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Phenylketonurias | D010661 | — | E70.0 | — | 1 | 6 | — | 3 | 10 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 3 | 1 | — | 1 | 6 |
Ischemic stroke | D000083242 | — | — | 4 | 2 | 1 | — | — | 5 |
Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 1 | — | 2 | 3 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | 1 | 1 | — | — | 3 |
Essential hypertension | D000075222 | — | I10 | — | — | 1 | — | 1 | 2 |
Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | 1 | 1 | — | — | 1 |
Hemostatic disorders | D020141 | — | — | — | 1 | 1 | — | — | 1 |
Renal insufficiency | D051437 | — | N19 | — | — | 1 | — | — | 1 |
Body-weight trajectory | D000077962 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 19 | 1 | — | — | 1 | 20 |
Thrombosis | D013927 | — | — | — | 1 | — | — | 4 | 5 |
Pharmacokinetics | D010599 | — | — | 2 | 1 | — | — | — | 3 |
Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | — | 2 | 3 |
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | 1 | — | — | 1 | 2 |
Intermittent claudication | D007383 | EFO_0003876 | I73.9 | 1 | 1 | — | — | — | 2 |
Stroke | D020521 | EFO_0000712 | I63.9 | 2 | 1 | — | — | — | 2 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
Meningioma | D008579 | EFO_0003098 | D32.9 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug interactions | D004347 | — | — | 3 | — | — | — | — | 3 |
Ischemia | D007511 | EFO_0000556 | — | 3 | — | — | — | — | 3 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | — | — | — | — | 2 |
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | — | — | — | — | 2 |
Sinusitis | D012852 | EFO_0007486 | J32 | 1 | — | — | — | 1 | 2 |
Nasal polyps | D009298 | — | J33 | 1 | — | — | — | 1 | 2 |
Rhinosinusitis | D000096825 | — | — | 1 | — | — | — | 1 | 2 |
Long qt syndrome | D008133 | HP_0001657 | I45.81 | 1 | — | — | — | — | 1 |
Pharmacological phenomena | D000069437 | — | — | 1 | — | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
St elevation myocardial infarction | D000072657 | — | — | — | — | — | — | 3 | 3 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 3 | 3 |
No-reflow phenomenon | D054318 | — | — | — | — | — | — | 2 | 2 |
Angioplasty | D017130 | — | — | — | — | — | — | 1 | 1 |
Coronary angiography | D017023 | — | — | — | — | — | — | 1 | 1 |
Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
Hemangioendothelioma | D006390 | — | — | — | — | — | — | 1 | 1 |
Exercise test | D005080 | EFO_0004328 | — | — | — | — | — | 1 | 1 |
Premature cardiac complexes | D005117 | — | I49.40 | — | — | — | — | 1 | 1 |
Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
Drug common name | Verapamil |
INN | verapamil |
Description | 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile is a tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group. It is a tertiary amino compound, an aromatic ether, a polyether and a nitrile. |
Classification | Small molecule |
Drug class | coronary vasodilators (verapamil type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC |
PDB | — |
CAS-ID | 52-53-9 |
RxCUI | — |
ChEMBL ID | CHEMBL6966 |
ChEBI ID | 77733 |
PubChem CID | 2520 |
DrugBank | DB00661 |
UNII ID | CJ0O37KU29 (ChemIDplus, GSRS) |